STOCK TITAN

MANNKIND (MNKD) SEC Filings, May 14-22, 2026

MNKD NASDAQ

MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.

The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.

Rhea-AI Summary

Binder Steven B. reported acquisition or exercise transactions in this Form 4 filing.

MannKind Corporation director Steven B. Binder reported receiving a grant of restricted stock units under the company’s equity compensation program. He was awarded 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.

The filing notes that these restricted stock units vested on May 20, 2026, but the underlying shares will not be delivered until Binder experiences a separation of service from MannKind’s board of directors. After this grant, he holds 82,781 restricted stock units directly, highlighting a compensation-related equity award rather than an open-market share purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
insider
-
Rhea-AI Summary

Grancio Jennifer reported acquisition or exercise transactions in this Form 4 filing.

MannKind Corp director Jennifer Grancio reported a compensation-related equity award and updated holdings. She received a grant of 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.

The restricted stock units vested on May 20, 2026, but the underlying shares will only be delivered after her separation of service from MannKind’s board of directors. Following the reported transactions, she holds 110,701 shares of common stock directly, alongside the newly granted 82,781 restricted stock units. A footnote also clarifies that 134,114 shares representing deferred restricted stock units had been inadvertently included in prior reported common stock holdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
insider
-
Rhea-AI Summary

MannKind Corporation director Anthony C. Hooper reported equity-based compensation in the form of restricted stock units (RSUs). On May 20, 2026, he received an award of 16,556 RSUs, each representing a contingent right to one share of MannKind common stock, which vested that day but will only be delivered after he separates from the board.

On the same date, he also received a second grant of 82,781 RSUs in lieu of his annual cash retainer as a non-employee director. This award vests immediately, with share delivery likewise deferred until his separation from board service. These are compensation-related acquisitions, not open-market purchases or sales of MannKind shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
insider
Rhea-AI Summary

Shannon James Samuel reported acquisition or exercise transactions in this Form 4 filing.

MannKind Corporation director James Samuel Shannon reported new equity awards and updated his share holdings. The filing shows he holds 36,458 shares of MannKind common stock directly. He also received two grants of restricted stock units (RSUs) tied to MannKind common stock.

One RSU grant covers 16,556 units that vested on May 20, 2026, but the underlying shares will only be delivered after he separates from service on MannKind’s board. A second grant of 82,781 RSUs was awarded in lieu of an annual cash retainer for non‑employee directors and vests immediately, with share delivery also deferred until board service ends. Each RSU represents the right to receive one share of MannKind common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
insider
-
Rhea-AI Summary

MANNKIND CORP Chief People & Workpl Officer Stuart A. Tross reported acquiring 33,898 shares of common stock at $2.95 per share. The shares were purchased through the company’s Market Price Stock Purchase Plan, which was approved by the Board of Directors on May 20, 2026. Following this transaction, he directly owns 1,026,122 common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
insider
-
Rhea-AI Summary

MannKind Corp executive Dominic Marasco, President of the Endocrine Business Unit, reported an acquisition of company stock through a compensation-related plan. He received 8,474 shares of common stock at $2.95 per share under the issuer's Market Price Stock Purchase Plan, which was approved by the board on May 20, 2026. Following this award, his directly held position increased to 344,246 shares of common stock, which includes 2,343 shares acquired under the issuer's Employee Stock Purchase Plan on December 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
insider
Rhea-AI Summary

MUNDKUR CHRISTINE reported acquisition or exercise transactions in this Form 4 filing.

MannKind Corp director Christine Mundkur reported a new equity award and clarified prior holdings. She received a grant of 82,781 restricted stock units, each representing a contingent right to receive one share of MannKind common stock.

The restricted stock units vested on May 20, 2026, but the underlying shares will not be delivered until she separates from service on MannKind’s board of directors. Following the reported activity, she directly holds 27,675 shares of MannKind common stock. A footnote states that 226,818 shares representing deferred restricted stock units were inadvertently included in earlier reported common stock holdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
insider
-
Rhea-AI Summary

Kay Sabrina reported acquisition or exercise transactions in this Form 4 filing.

MannKind Corporation director Sabrina Kay reported a compensation-related stock award rather than an open-market trade. On May 20, 2026, she received a grant of 82,781 restricted stock units (RSUs), each representing a contingent right to one share of MannKind common stock. The RSU grant is shown with a price of $0.0000 per unit, reflecting that it is an award, not a purchase. The filing also shows she holds 107,033 shares of common stock directly after the reported transactions and 82,781 RSUs outstanding. A footnote explains that 158,567 shares representing deferred restricted stock units had been inadvertently included in prior common-stock holdings and are now correctly reflected as deferred RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
insider
-
Rhea-AI Summary

MannKind Corporation reported results from its 2026 Annual Meeting of Stockholders held on May 20, 2026. Stockholders elected nine directors, each receiving over 140 million shares voted in favor, with sizable broker non-votes recorded on the election items.

Stockholders approved, on an advisory basis, the compensation of MannKind’s named executive officers, with 137,332,418 shares voted for, 16,295,138 against, 1,303,497 abstaining, and 78,531,407 broker non-votes. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for 2026, with 221,079,329 shares for, 8,759,982 against, and 3,623,149 abstaining.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
current report
Rhea-AI Summary

MannKind Corp officer David Thomson reported a proposed sale of 3,033 common shares, with an aggregate market value of $9,886.83 and an approximate sale date of May 12, 2026. He acquired the shares from MannKind Corp as restricted stock units on May 10, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
other

FAQ

How many MANNKIND (MNKD) SEC filings are available on StockTitan?

StockTitan tracks 91 SEC filings for MANNKIND (MNKD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for MANNKIND (MNKD)?

The most recent SEC filing for MANNKIND (MNKD) was filed on November 19, 2026.